Please login to the form below

Not currently logged in
Email:
Password:

EC green lights Volibris

GlaxoSmithKline has revealed that the European Commission has granted marketing authorisation for Volibris, which can now be prescribed across the EU market
GlaxoSmithKline (GSK) has revealed that the European Commission has granted marketing authorisation for Volibris, which can now be prescribed across the EU market.

Volibris (ambrisentan) has been developed to treat patients with pulmonary arterial hypertension (PAH). It is hoped that it will improve the exercise capacity of sufferers classified as functional class II and III by the World Health Organisation (WHO).

Nazzareno Galie, professor of cardiology and head of the Pulmonary Hypertension Centre at the University of Bologna, said: "Ambrisentan represents a development in the treatment of patients with PAH. It has demonstrated efficacy and safety in both functional class II and III patients. New treatments like this are important and make incremental improvements to patients' quality of life."

Patients diagnosed with PAH have an average life expectancy of 2.8 years, a figure that recent data indicates could be rising due to advances in diagnosis and treatment. The disease affects over 200,000 people globally and is a rare and fatal disorder causing complications of the arteries and lungs.

Professor Ardeschir Ghofrani, head of the pulmonary hypertension division at the University Hospital Giessen, Germany, said: "Ambrisentan's low risk of drug-drug interactions and low incidence of liver function test abnormalities offer important additional benefits to patients with PAH whose quality of life is already significantly compromised by this progressive life-threatening condition."

GSK plans to launch ambrisentan in Europe sometime during the summer of 2008.

28th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Indigenus

A global healthcare communications network dedicated to helping clients grow their brands. Unstuck, with an entrepreneurial and nimble spirit....

Latest intelligence

BrAInPME.png
The future of medical content: The personal touch
The purpose of delivering personalised content to HCPs is not just about customer experience, it's about improving healthcare. Our Commercial Director, Tib Catania discusses what ‘deep learning’ means for the...
Rise of the patient expert - an interview with Michael Seres
Founded by Michael Seres in 2011, 11 Health is a connected medical device company currently working to change the lives of patients using stoma bags. Content Marketing Manager Liz Inskip...
Making sense of Nutraceuticals in China
Published in eyeforpharma February 2017 by Marc Yates...

Infographics